BACKGROUND: Although the amygdala is thought to be a crucial brain region for negative affect, neuroimaging studies do not always show enhanced amygdala response to aversive stimuli in patients with anxiety disorders. Serotonin (5-HT)-related genotypes may contribute to interindividual variability in amygdala responsiveness. The short (s) allele of the 5-HT transporter linked polymorphic region (5-HTTLPR) and the T variant of the G-703T polymorphism in the tryptophan hydroxylase-2 (TPH2) gene have previously been associated with amygdala hyperresponsivity to negative faces in healthy controls. We investigated the influence of these polymorphisms on amygdala responsiveness to angry faces in patients with social anxiety disorder (SAD) compared with healthy controls. METHODS: We used positron emission tomography with oxygen 15-labelled water to assess regional cerebral blood flow in 34 patients with SAD and 18 controls who viewed photographs of angry and neutral faces presented in counterbalanced order. We genotyped all participants with respect to the 5-HTTLPR and TPH2 polymorphisms. RESULTS: Patients with SAD and controls had increased left amygdala activation in response to angry compared with neutral faces. Genotype but not diagnosis explained a significant portion of the variance in amygdala responsiveness, the response being more pronounced in carriers of s and/or T alleles. LIMITATIONS: Our analyses were limited owing to the small sample and the fact that we were unable to match participants on genotype before enrollment. In addition, other imaging techniques not used in our study may have revealed additional effects of emotional stimuli. CONCLUSION: Amygdala responsiveness to angry faces was more strongly related to serotonergic polymorphisms than to diagnosis of SAD. Emotion activation studies comparing amygdala excitability in patient and control groups could benefit from taking variation in 5-HT-related genes into account.
BACKGROUND: Although the amygdala is thought to be a crucial brain region for negative affect, neuroimaging studies do not always show enhanced amygdala response to aversive stimuli in patients with anxiety disorders. Serotonin (5-HT)-related genotypes may contribute to interindividual variability in amygdala responsiveness. The short (s) allele of the 5-HT transporter linked polymorphic region (5-HTTLPR) and the T variant of the G-703T polymorphism in the tryptophan hydroxylase-2 (TPH2) gene have previously been associated with amygdala hyperresponsivity to negative faces in healthy controls. We investigated the influence of these polymorphisms on amygdala responsiveness to angry faces in patients with social anxiety disorder (SAD) compared with healthy controls. METHODS: We used positron emission tomography with oxygen 15-labelled water to assess regional cerebral blood flow in 34 patients with SAD and 18 controls who viewed photographs of angry and neutral faces presented in counterbalanced order. We genotyped all participants with respect to the 5-HTTLPR and TPH2 polymorphisms. RESULTS:Patients with SAD and controls had increased left amygdala activation in response to angry compared with neutral faces. Genotype but not diagnosis explained a significant portion of the variance in amygdala responsiveness, the response being more pronounced in carriers of s and/or T alleles. LIMITATIONS: Our analyses were limited owing to the small sample and the fact that we were unable to match participants on genotype before enrollment. In addition, other imaging techniques not used in our study may have revealed additional effects of emotional stimuli. CONCLUSION: Amygdala responsiveness to angry faces was more strongly related to serotonergic polymorphisms than to diagnosis of SAD. Emotion activation studies comparing amygdala excitability in patient and control groups could benefit from taking variation in 5-HT-related genes into account.
Authors: Darren W Campbell; Jitender Sareen; Martin P Paulus; Philippe R Goldin; Murray B Stein; Jeffrey P Reiss Journal: Biol Psychiatry Date: 2006-12-22 Impact factor: 13.382
Authors: K Lira Yoon; Daniel A Fitzgerald; Mike Angstadt; Rosemary A McCarron; K Luan Phan Journal: Psychiatry Res Date: 2006-11-09 Impact factor: 3.222
Authors: Lise Gutknecht; Christian Jacob; Alexander Strobel; Claudia Kriegebaum; Johannes Müller; Yong Zeng; Christoph Markert; Andrea Escher; Jens Wendland; Andreas Reif; Rainald Mössner; Cornelius Gross; Burkhard Brocke; Klaus-Peter Lesch Journal: Int J Neuropsychopharmacol Date: 2006-12-19 Impact factor: 5.176
Authors: U Dannlowski; P Ohrmann; J Bauer; H Kugel; B T Baune; C Hohoff; A Kersting; V Arolt; W Heindel; J Deckert; T Suslow Journal: Genes Brain Behav Date: 2006-12-20 Impact factor: 3.449
Authors: Rebecca A Rhodes; Naga Venkatesha Murthy; M Alex Dresner; Sudhakar Selvaraj; Nikolaos Stavrakakis; Syed Babar; Philip J Cowen; Paul M Grasby Journal: J Neurosci Date: 2007-08-22 Impact factor: 6.167
Authors: Clas Linnman; Mohamed A Zeidan; Sharon C Furtak; Roger K Pitman; Gregory J Quirk; Mohammed R Milad Journal: Am J Psychiatry Date: 2012-04 Impact factor: 18.112
Authors: Emily M Drabant; Wiveka Ramel; Michael D Edge; Luke W Hyde; Janice R Kuo; Philippe R Goldin; Ahmad R Hariri; James J Gross Journal: Am J Psychiatry Date: 2012-04 Impact factor: 18.112
Authors: Vanda Faria; Lieuwe Appel; Fredrik Åhs; Clas Linnman; Anna Pissiota; Örjan Frans; Massimo Bani; Paolo Bettica; Emilio M Pich; Eva Jacobsson; Kurt Wahlstedt; Mats Fredrikson; Tomas Furmark Journal: Neuropsychopharmacology Date: 2012-05-23 Impact factor: 7.853
Authors: Guo-Lin Chen; Melinda A Novak; Jerrold S Meyer; Brian J Kelly; Eric J Vallender; Gregory M Miller Journal: Horm Behav Date: 2009-11-06 Impact factor: 3.587